Literature DB >> 15897348

Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth.

Rudolf Kirchmair1, Dirk H Walter, Masaaki Ii, Kilian Rittig, Anne B Tietz, Toshinori Murayama, Costanza Emanueli, Marcy Silver, Andrea Wecker, Carole Amant, Peter Schratzberger, Young-Sup Yoon, Alberto Weber, Eleftheria Panagiotou, Kenneth M Rosen, Ferdinand H Bahlmann, Lester S Adelman, David H Weinberg, Allan H Ropper, Jeffrey M Isner, Douglas W Losordo.   

Abstract

BACKGROUND: Toxic neuropathies induced by cisplatin and other chemotherapeutic agents are important clinical problems because of their high incidence, their lack of effective treatment, and the fact that neuropathy represents a dose-limiting factor for these therapies. The pathogenic basis for toxic neuropathies induced by chemotherapeutic agents has not been completely elucidated. METHODS AND
RESULTS: We investigated the hypothesis that experimental toxic neuropathy results from an antiangiogenic effect of these drugs, resulting in destruction of the vasa nervorum, and accordingly that the neuropathy could be prevented or reversed by locally administered VEGF gene transfer without augmenting tumor growth. In an animal model of cisplatin-induced neuropathy, nerve blood flow was markedly attenuated, and there was a profound reduction in the number of vasa nervorum associated with marked endothelial cell apoptosis, resulting in a severe peripheral neuropathy with focal axonal degeneration characteristic of ischemic neuropathy. After intramuscular gene transfer of naked plasmid DNA encoding VEGF-1 in animals with an established neuropathy, vascularity and blood flow returned to levels similar to those of control rats, peripheral nerve function was restored, and histological nerve architecture was normalized. Gene therapy administered in parallel with cisplatin chemotherapy completely attenuated endothelial cell apoptosis and inhibited destruction of nerve vasculature, deterioration of nerve function, and axonal degeneration. In a rat tumor model, VEGF gene transfer administered locally did not alter tumor growth or vascularity.
CONCLUSIONS: These findings implicate microvascular damage as the basis for toxic neuropathy induced by cisplatin and suggest that local angiogenic gene therapy may constitute a novel prevention or treatment for this disorder without augmenting tumor growth or vascularization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897348     DOI: 10.1161/CIRCULATIONAHA.104.470849

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  16 in total

1.  Antitumour and antiangiogenic activities of [Pt(O,O'-acac)(γ-acac)(DMS)] in a xenograft model of human renal cell carcinoma.

Authors:  A Muscella; C Vetrugno; F Biagioni; N Calabriso; M T Calierno; F Fornai; S A De Pascali; S Marsigliante; F P Fanizzi
Journal:  Br J Pharmacol       Date:  2016-07-22       Impact factor: 8.739

Review 2.  Chemotherapy-induced peripheral neuropathy: A current review.

Authors:  Nathan P Staff; Anna Grisold; Wolfgang Grisold; Anthony J Windebank
Journal:  Ann Neurol       Date:  2017-06-05       Impact factor: 10.422

3.  Topical combinations aimed at treating microvascular dysfunction reduce allodynia in rat models of CRPS-I and neuropathic pain.

Authors:  J Vaigunda Ragavendran; André Laferrière; Wen Hua Xiao; Gary J Bennett; Satyanarayana S V Padi; Ji Zhang; Terence J Coderre
Journal:  J Pain       Date:  2013-01       Impact factor: 5.820

4.  Effects of cisplatin on the contractile function of thoracic aorta of Sprague-Dawley rats.

Authors:  Ying Jiang; Shigang Shan; Tieer Gan; Xiaoyun Zhang; Xianghong Lu; Hu Hu; Yihua Wu; Jianzhong Sheng; Jun Yang
Journal:  Biomed Rep       Date:  2014-08-19

5.  Fibrates protect against vascular endothelial dysfunction induced by paclitaxel and carboplatin chemotherapy for cancer patients: a pilot study.

Authors:  Ayako Watanabe; Akiko Tanabe; Risa Maruoka; Kiyoko Nakamura; Koji Hatta; Yoshihiro J Ono; Yoshito Terai; Masahide Ohmichi
Journal:  Int J Clin Oncol       Date:  2014-12-26       Impact factor: 3.402

6.  Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer.

Authors:  Stephen Sands; Elena J Ladas; Kara M Kelly; Michael Weiner; Meiko Lin; Deborah Hughes Ndao; Amie Dave; Linda T Vahdat; Julia Glade Bender
Journal:  Support Care Cancer       Date:  2016-11-09       Impact factor: 3.603

7.  Neuronal FLT1 receptor and its selective ligand VEGF-B protect against retrograde degeneration of sensory neurons.

Authors:  Joke Dhondt; Eve Peeraer; An Verheyen; Rony Nuydens; Ian Buysschaert; Koen Poesen; Katie Van Geyte; Manu Beerens; Masabumi Shibuya; Jody J Haigh; Theo Meert; Peter Carmeliet; Diether Lambrechts
Journal:  FASEB J       Date:  2011-01-19       Impact factor: 5.191

8.  Altered temporal-parietal morphological similarity networks in non-small cell lung cancer patients following chemotherapy: an MRI preliminary study.

Authors:  Gong Chen; Chuan Wu; Yuan Liu; Zengyi Fang; Liping Luo; Xin Lai; Weidong Wang; Li Dong
Journal:  Brain Imaging Behav       Date:  2022-08-02       Impact factor: 3.224

Review 9.  Vascular endothelial growth factor: a neurovascular target in neurological diseases.

Authors:  Christian Lange; Erik Storkebaum; Carmen Ruiz de Almodóvar; Mieke Dewerchin; Peter Carmeliet
Journal:  Nat Rev Neurol       Date:  2016-07-01       Impact factor: 42.937

Review 10.  Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced Neuropathy.

Authors:  Gerald M Higa; Corbin Sypult
Journal:  Clin Med Insights Oncol       Date:  2016-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.